

Opioid Maintenance Pharmacotherapy: An 8-Hour Course for Clinicians

You are registered for the 8-Hour Clinicians Course during the 2021 AATOD Conference. The course is presented in the virtual format. To facilitate the delivery of this course, the lecture presentations of this course will be available for viewing beginning **Thursday, April 1st** on the Conference Website. You may access the presentations by logging in to the Conference website using your registration credentials (email and Registration ID).

On **Sunday, April 11, 2021**, there will be a **required** 3-Hour Live Case Study and Q&A Session through a Zoom Meeting beginning at 9:00 AM **Pacific Daylight Time (PDT)**.

We have outlined the recommended timeline for viewing the presentations prior to attending the Live Session. Please note, these are only suggested, however, all presentations must be viewed by **Wednesday, April 14th** in order to receive credit.

[VIEW PRESENTATIONS](#)

Suggested Viewing	Subject Areas	Presenter
Thursday 4/1	“Welcome and Introduction”	Stoller
	“Epidemiology of the Opioid Epidemic”	
	“The OTP as a Unique Treatment Setting” (<i>covering regulations and accreditation, patient assessment, comprehensive treatment, multidisciplinary team approach</i>)	Parekh
Friday 4/2	“Opioid Pharmacology”	McCarroll
	“Methadone Induction and Early Stabilization”	McNicholas
Monday 4/5	“Methadone Stabilization”	Stoller
	“Pregnancy and OUD”	Ruble
Tuesday 4/6	“Adverse Drug Effects, Drug Interactions” (<i>including cardiac effects, EKG monitoring & FDA Warning</i>)	McCarroll
	“Buprenorphine and Naltrexone”	McNicholas
Wednesday 4/7	“Co-occurring Medical Conditions”	McCarroll
	“Co-occurring Psychiatric Disorders and Polysubstance Use”	Ruble
Thursday 4/8	“Toxicology Testing in the OTP”	Parekh
	“Pain Management”	Stoller
Sunday 4/11 9:00 AM PDT - 12:00 PM PDT	REQUIRED: 3-Hour Live Case Study and Q&A Session Join Live Session	All

NEED HELP?

For technical support, click [here](#). For questions regarding the conference, contact meetings@aatod.org. For registration assistance, contact aatod@showcare.com.

Referenced Bibliography

1. Leshner, A.I. and Mancher, M., Eds. Medications for Opioid Use Disorder Save Lives. A Consensus Study Report of the National Academy of Sciences Engineering Medicine. The National Academies Press. 2019.
2. Parrino, M. Using Medication Assisted Treatment to Treat Opioid Use Disorder: Learning from past experience to guide policy. Heroin Addict Related Clin Probl, 2019

Epidemiology

3. Results from the 2018 National Survey on Drug Use and Health: Summary of National Findings, <http://www.samhsa.gov/data/NSDUH/2k10NSDUH/2k10Results.htm>
4. Results from the 2008 National Survey on Drug Use and Health: National Findings, <http://www.oas.samhsa.gov/nsduh/2k8nsduh/2k8Results.pdf>
5. A Day in the Life of American Adolescents: Substance Use Facts Update, The OAS Report, SAMHSA, Office of Applied Studies, April 29, 2010
6. Trends in Emergency Department Visits Involving Nonmedical Use Narcotic Pain Relievers, The DAWN Report, <http://DAWNInfo.samhsa.gov>
7. Mary Jeanne Kreek, K. Steven LaForge & Eduardo Butelman, Pharmacotherapy of addictions, *Nature Reviews Drug Discovery* 1, 710-726 (September 2002)
8. Cicero, T.J., Ellis, M.E., Surratt, H.L and Kurtz, S.P. The Changing Face of Heroin Use in the United States: A retrospective analysis of the past 50 years. *JAMA Psychiatry* 2014.

Methadone-Associated Deaths

1. Methadone Mortality – A 2010 Reassessment. http://dpt.samhsa.gov/pdf/Methadone_Briefing_Paper.pdf
2. GAO-09-341, Methadone-Associated Overdose Deaths, Report to Congressional Requesters, March 2009
3. Shields, LB, et. al, Methadone Toxicity Fatalities: A Review of Medical Examiner Cases In A Large Metropolitan Area, *J. Forensic Sci*, November 2007, Vol. 52, No. 6
4. [Modesto-Lowe V](#), [Brooks D](#), [Petry N](#), Methadone deaths: risk factors in pain and addicted populations., *J Gen Intern Med*. 2010 Apr;25(4):305-9. Epub 2010 Jan 20.
5. Letsky MC, Zumwalt RE, Seifert SA, Benson BE, Cause of Death Conundrum With Methadone Use: A Case Report. *Am J Forensic Med Pathol*. 2010 Feb 25.
6. Paulozzi LJ, Logan JE, Hall AJ, McKinsty E, Kaplan JA, Crosby AE. A comparison of drug overdose deaths involving methadone and other opioid analgesics in West Virginia. *Addiction*. 2009 Sep;104(9):1541-8.
7. Graham NA, Merlo LJ, Goldberger BA, Gold MS. Methadone- and heroin-related deaths in Florida. *Am J Drug Alcohol Abuse*. 2008;34(3):347-53.
8. Dart, R.C, Surratt, H.L., Cicero, T.J., Parrino, M.W., Severtson, S. G., Bucher-Bartelson, B., and Green, J.L. Trends in Opioid Analgesic Abuse and Mortality in the United States. *NEJM* 2015 372: 241-8.

Opioid Pharmacology

1. Eap, CB, et al. Interindividual Variability of the Pharmacokinetics of Methadone. Implications for the treatment of Opioid Dependence. *Clin Pharmacokinet* 2002 41 (14) 1153-1193.
2. Smith, HD, Opioid Metabolism, *Mayo Clin Proc*, July 2009, 84(7):613-624.
3. Li Y, Kantelip JP, Gerritsen-van Schieveen P, Davani S. Interindividual variability of methadone response: impact of genetic polymorphism. [Mol Diagn Ther](#). 2008;12(2):109-24.
4. Fredheim OM, Moksnes K, Borchgrevink PC, Kaasa S, Dale O., Clinical pharmacology of methadone for pain. [Acta Anaesthesiol Scand](#). 2008 Aug;52(7):879-89. Epub 2008 Mar 7.
5. Rostami-Hodjegan, A., et. al, Population pharmacokinetics of methadone in opiate users: characterization of time dependent changes, *Br J Clin Pharmacol* 1999, 48:43-52
6. Wolfe, K., et. al, The Pharmacokinetics of methadone in health subjects and opiate users, *Br J Clin Pharmacol* 1997, 44:325-334.

Neurobiology

1. Volkow, Nora D., et al. "Neurobiologic Advances from the Brain Disease Model of Addiction." *New England Journal of Medicine*, vol. 374, no. 4, 2016, pp. 363–371.
2. Stimmel B, Kreek MJ. Neurobiology of addictive behaviors and its relationship to methadone maintenance. Oct/Nov 2000, *Mt Sinai Journal of Medicine*, Vol 67 Nos. 5&6.
3. Bechara, A, Decision making, impulse control, and loss of will power to resist drugs: a neurocognitive perspective. November 2005, *Nature Neuroscience* Vol. 8 No.11.
4. Nasir H, et. al, The hidden island of addiction: the insula, *Trends in Neurosciences*, 2008, Vol xxx, No.x

Treatment Options

- 1 Neufeld K, Kidorf M, King V, Stoller K, Clark M, Peirce J, Brooner RK. [Using enhanced and integrated services to improve response to standard methadone treatment: changing the clinical infrastructure of treatment networks](#). *J Subst Abuse Treat*. 2010 Mar;38(2):170-7
- 2 Kinlock TW, Gordon MS, Schwartz RP, Fitzgerald TT, O'Grady KE. A randomized clinical trial of methadone maintenance for prisoners: results at 12 months post release. [J Subst Abuse Treat](#). 2009 Oct;37(3):277-85. Epub 2009 Mar 31.
- 3 Oviedo-Joekes E, Brissette S, Marsh DC, Lauzon P, Guh D, Anis A, Schechter MT. Diacetylmorphine versus methadone for the treatment of opioid addiction. *N Engl J Med*. 2009 Aug 20;361(8):777-86.
- 4 Stotts AL, Dodrill CL, Kosten TR. [Opioid dependence treatment: options in pharmacotherapy](#). *Expert Opin Pharmacother*. 2009 Aug;10(11):1727-40. Review
- 5 Sorensen JL, Andrews S, Delucchi KL, Greenberg B, Guydish J, Masson CL, Shopshire M. [Methadone patients in the therapeutic community: a test of equivalency](#). *Drug Alcohol Depend*. 2009 Feb 1;100(1-2):100-6
- 6 Kleber HD, Methadone maintenance 4 decades later: Thousands of Lives Saved But Still Controversial. *JAMA* 2008;300(19):2303-2305.
- 7 Joseph H, Stancliff S, Langrod J. Methadone maintenance treatment (MMT): a review of historical and clinical issues. [Mt Sinai J Med](#). 2000 Oct-Nov;67(5-6):347-64.
- 8 Paul G. Barnett, Ph.D., and Sally S. Hui, B.A, The Cost-Effectiveness of Methadone Maintenance, Oct/Nov 2000, *Mt Sinai Journal of Medicine*, Vol 67 Nos. 5&6.

American Association for the Treatment of Opioid Dependence, Inc.
Opioid Maintenance Pharmacotherapy – A Course for Clinicians

- 9 Merrill JO, Jackson TR, Schulman BA, Saxon AJ, Awan A, Kapitan S, Carney M, Brumback LC, Donovan D. [Methadone medical maintenance in primary care. An implementation evaluation.](#) J Gen Intern Med. 2005 Apr;20(4):344-9.

Methadone Induction / Stabilization

1. Klamon, Stacey L., et al. "Treating Women Who Are Pregnant and Parenting for Opioid Use Disorder and the Concurrent Care of Their Infants and Children." Journal of Addiction Medicine, vol. 11, no. 3, 2017, pp. 178–190.
2. Kaltenbach, Karol, and Hendree E. Jones. "Neonatal Abstinence Syndrome." Journal of Addiction Medicine, vol. 10, no. 4, 2016, pp. 217–223.
3. Trafton, JA, Determining Effective Methadone Doses for Individual Opioid-Dependent Patients, PLOS Medicine March 2006, Vol 3 Issue 3.
4. Leavitt, SB, Methadone Dosing and Safety In the Treatment of Opioid Addiction, AT Forum, www.atforum.com
5. Srivastava A, Kahan M. Methadone induction doses: are our current practices safe? [J Addict Dis.](#) 2006;25(3):5-13.
6. [Greenwald MK](#), Early impact of methadone induction for heroin dependence: differential effects of two dose sequences in a randomized controlled study. [Exp Clin Psychopharmacol.](#) 2006 Feb;14(1):52-67.
7. Baxter, L.E., Campbell, A., DeShields, M., Levounis, P., Martin, J., McNicholas, L., Payte, J.T., Salsitz, E.A., Taylor, T., and Wilford, B.B. Safe Methadone Induction and Stabilization: Report of an Expert Panel. J. Addict Med 2013; 7:377-386.

Drug-Drug Interactions

1. Gruber VA, McCance-Katz EF, Methadone, buprenorphine, and street drug interactions with antiretroviral medications, Curr HIV/AIDS Rep. 2010 Aug;7(3):152-60.
2. Keller GA, Ponte ML, Di Girolamo G, [Other drugs acting on nervous system associated with QT-interval prolongation.](#) Curr Drug Saf. 2010 Jan;5(1):105-11. Review
3. McCance-Katz EF, Sullivan LE, Nallani S. [Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review.](#) Am J Addict. 2010 Jan-Feb;19(1):4-16
4. McCance-Katz EF, Mandell TW, [Drug interactions of clinical importance with methadone and buprenorphine.](#) Am J Addict. 2010 Jan-Feb;19(1):2-3
5. Batkis MF, Treisman GJ, Angelino AF, [Integrated opioid use disorder and HIV treatment: rationale, clinical guidelines for addiction treatment, and review of interactions of antiretroviral agents and opioid agonist therapies.](#)
6. Izzo AA, Ernst E. [Interactions between herbal medicines and prescribed drugs: an updated systematic review.](#) Drugs. 2009;69(13):1777-98
7. Jeffrey, M.M., Hooten, M., Jena, A.B., Ross, J.S., Shah, N.D and Karaca-Mandic, P. Rates of Physician Coprescribing of Opioids and Benzodiazepines After the Release of the Centers for Disease Control and Prevention Guidelines in 2016. JAMA Network Open 2019;2:e198325.

Cardiac Considerations

1. Anchersen K, Hansteen V, Gossop M, Clausen T, Waal H, [Opioid maintenance patients with QTc prolongation: Congenital long QT syndrome mutation may be a contributing risk factor](#). Drug Alcohol Depend. 2010 Aug 9
2. Fareed A, Vayalapalli S, Byrd-Sellers J, Casarella J, Drexler K, Amar R, Smith-Cox J, Lutchman TS. [Onsite QTc interval screening for patients in methadone maintenance treatment](#). J Addict Dis. 2010 Jan;29(1):15-22.
3. Fonseca F, Marti-Almor J, Pastor A, Cladellas M, Farré M, de la Torre R, Torrens M. Prevalence of long QTc interval in methadone maintenance patients. Drug Alcohol Depend. 2009 Jan 1;99(1-3):327-32
4. Wallner C, Stöllberger C, Hlavín A, Finsterer J, Hager I, Hermann P. [Electrocardiographic abnormalities in opiate addicts](#). Addiction. 2008 Dec;103(12):1987-93.
5. Peles E, Bodner G, Kreek MJ, Rados V, Adelson M. [Corrected-QT intervals as related to methadone dose and serum level in methadone maintenance treatment \(MMT\) patients: a cross-sectional study](#). Addiction. 2007 Feb;102(2):289-300.
6. Latowsky M, Methadone, Death, Dosage and Torsade de Pointes: Risk-Benefit Policy Implications. *Journal of Psychoactive Drugs*; Dec 2006; 38, 4; 513-519
7. Krantz MJ, Lowery CM, Martell BA, Gourevitch MN, Arnsten JH. [Effects of methadone on QT-interval dispersion](#). Pharmacotherapy. 2005 Nov;25(11):1523-9
8. Pearson EC, Woosley RL. [QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system](#). Pharmacoepidemiol Drug Saf. 2005 Nov;14(11):747-53
9. Cruciani RA, Sekine R, Homel P, Lussier D, Yap Y, Suzuki Y, Schweitzer P, Yancovitz SR, Lapin JA, Shaiova L, Sheu RG, Portenoy RK. [Measurement of QTc in patients receiving chronic methadone therapy](#). J Pain Symptom Manage. 2005 Apr;29(4):385-91
10. Krantz MJ, Rowan SB, Mehler PS. [Cocaine-related torsade de pointes in a methadone maintenance patient](#). J Addict Dis. 2005;24(1):53-60
11. Maremmanni I, Pacini M, Cesaroni C, Lovrecic M, Perugi G, Tagliamonte A. [QTc interval prolongation in patients on long-term methadone maintenance therapy](#). Eur Addict Res. 2005;11(1):44-9
12. Krantz MJ, Kutinsky IB, Robertson AD, Mehler PS. [Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes](#). Pharmacotherapy. 2003 Jun;23(6):802-5
13. Chou, R., Cruciani, R.A., Fiellin, D.A., Compton, P., Farrar, J.T., Haigney, M.C., Inturrisi, C., Knight, J.R., Otis –Green, S., Marcus, S.M., Mehta, D., Meyer, M.C., Portenoy, R., Savage, S., Strain, E., Walsh, S. and Zeltzer, L. Methadone Safety Guidelines: Methadone Safety: A Clinical Practice Guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society. J. of Pain 2014; 15: 321-337.

Medical Comorbidity

1. Walley AY, Farrar D, Cheng DM, Alford DP, Samet JH. [Are opioid dependence and methadone maintenance treatment \(MMT\) documented in the medical record? A patient safety issue](#). J Gen Intern Med. 2009 Sep;24(9):1007-11
2. Mancino M, Curran G, Han X, Allee E, Humphreys K, Booth BM. [Predictors of attrition from a national sample of methadone maintenance patients](#). Am J Drug Alcohol Abuse. 2010 May;36(3):155-60.

**American Association for the Treatment of Opioid Dependence, Inc.
Opioid Maintenance Pharmacotherapy – A Course for Clinicians**

3. Rajaratnam R, Sivesind D, Todman M, Roane D, Seewald R. [The aging methadone maintenance patient: treatment adjustment, long-term success, and quality of life.](#) J Opioid Manag. 2009 Jan-Feb;5(1):27-37
4. Litwin AH, Harris KA Jr, Nahvi S, Zamor PJ, Soloway IJ, Tenore PL, Kaswan D, Gourevitch MN, Arnsten JH. [Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program.](#) J Subst Abuse Treat. 2009 Jul;37(1):32-40. Epub 2008 Nov 28
5. [Kreek MJ, Talal AH, Piccolo P](#) Treating chronic hepatitis C in recovering opiate addicts: yes, we can. [Dig Liver Dis.](#) 2009 Apr;41(4):308-10. Epub 2009 Feb 23.
6. Liver Transplantation in the United States, 1999-2008
http://www.ustransplant.org/annual_reports/current/Chapter_IV_AR_CD.htm#4
7. Thomas F. Kresina¹, Diana Sylvestre², Leonard Seeff³, Alain H. Litwin⁴, Kenneth Hoffman¹, Robert Lubran¹ and H. Westley Clark, Hepatitis Infection in the Treatment of Opioid Dependence and Abuse, Substance Abuse: Research and Treatment 2008:1
8. M. S. Sulkowski¹ and Y. Benhamou, Therapeutic issues in HIV/HCV-coinfected patients. Journal of Viral Hepatitis, 2007, 14, 371–386
9. Bekker LG, Wood R. [The changing natural history of tuberculosis and HIV coinfection in an urban area of hyperendemicity.](#) Clin Infect Dis. 2010 May 15;50 Suppl 3:S208-14. Review.
10. Gourevitch MN, Chatterji P, Deb N, Schoenbaum EE, Turner BJ. [On-site medical care in methadone maintenance: associations with health care use and expenditures.](#) J Subst Abuse Treat. 2007 Mar;32(2):143-51.
11. Herman M, Gourevitch MN. [Integrating primary care and methadone maintenance treatment: implementation issues.](#) J Addict Dis. 1997;16(1):91-102
12. Richter KP, Choi WS, McCool RM, Harris KJ, Ahluwalia JS. [Smoking cessation services in U.S. methadone maintenance facilities.](#) Psychiatr Serv. 2004 Nov;55(11):1258-64
13. Winklbaur B, Kopf N, Ebner N, Jung E, Thau K, Fischer G. [Treating pregnant women dependent on opioids is not the same as treating pregnancy and opioid dependence: a knowledge synthesis for better treatment for women and neonates.](#) Addiction. 2008 Sep;103(9):1429-40. Review.PMID
14. Revised Recommendations for HIV Testing of Adults, Adolescents, and Pregnant Women in Health-Care Settings. <http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5514a1.htm>
15. HIV Counseling with Rapid Tests.
http://www.cdc.gov/hiv/topics/testing/resources/factsheets/rt_counseling.htm
- 16.

Pain Management

1. Peles E, Schreiber S, Hetzroni T, Adelson M, Defrin R. [The Differential Effect of Methadone Dose and of Chronic Pain on Pain Perception of Former Heroin Addicts Receiving Methadone Maintenance Treatment.](#) J Pain. 2010 Jun 18.
2. Barry DT, Beitel M, Cutter CJ, Joshi D, Falcioni J, Schottenfeld RS. [Conventional and non-conventional pain treatment utilization among opioid dependent individuals with pain seeking methadone maintenance treatment: A needs assessment study.](#) J Addict Med. 2009 Sep;18(5):379-385
3. Barry DT, Beitel M, Garnet B, Joshi D, Rosenblum A, Schottenfeld RS. [Relations among psychopathology, substance use, and physical pain experiences in methadone-maintained patients.](#) J Clin Psychiatry. 2009 Sep;70(9):1213-8.

**American Association for the Treatment of Opioid Dependence, Inc.
Opioid Maintenance Pharmacotherapy – A Course for Clinicians**

4. Barry DT, Beitel M, Cutter CJ, Garnet B, Joshi D, Schottenfeld RS, Rounsaville BJ. [Allopathic, complementary, and alternative medical treatment utilization for pain among methadone-maintained patients](#). Am J Addict. 2009 Sep-Oct;18(5):379-85
5. Blinderman CD, Sekine R, Zhang B, Nillson M, Shaiova L. [Methadone as an analgesic for patients with chronic pain in methadone maintenance treatment programs \(MMTPs\)](#). J Opioid Manag. 2009 Mar-Apr;5(2):107-14.
6. Barry DT, Beitel M, Joshi D, Schottenfeld RS. [Pain and substance-related pain-reduction behaviors among opioid dependent individuals seeking methadone maintenance treatment](#). Am J Addict. 2009 Mar-Apr;18(2):117-21.
7. Berg KM, Arnsten JH, Sacajiu G, Karasz A. [Providers' experiences treating chronic pain among opioid-dependent drug users](#). J Gen Intern Med. 2009 Apr;24(4):482-8
8. Hines S, Theodorou S, Williamson A, Fong D, Curry K. [Management of acute pain in methadone maintenance therapy in-patients](#). Drug Alcohol Rev. 2008 Sep;27(5):519-23.
9. Cruciani RA, Esteban S, Seewald RM, Altילו T, Bookbinder M, Sheu R, Portenoy RK. [MMTP patients with chronic pain switching to pain management clinics. A problem or an acceptable practice?](#) Pain Med. 2008 Apr;9(3):359-64
10. Seddon R. Savage, M.D., M.S. Kenneth L. Kirsh, Ph.D. Steven D. Passik, Ph.D. Challenges in Using Opioids to Treat Pain in Persons With Substance Use Disorders . Addictions Science & Clinical Practice June 2008. <http://www.nida.nih.gov/PDF/ascp/vol4no2/Challenges.pdf>
11. Graig, L., Olchefske, I. and Alper, J. Pain Management for People with Serious Illness in the Context of the Opioid Use Epidemic; Proceedings of a Workshop. The National Academies Press, 2019.

Psychiatric Comorbidity

1. Wedekind D, Jacobs S, Karg I, Luedecke C, Schneider U, Cimander K, Baumann P, Ruether E, Poser W, Havemann-Reinecke U. [Psychiatric comorbidity and additional abuse of drugs in maintenance treatment with L- and D,L-methadone](#). World J Biol Psychiatry. 2010 Mar;11(2 Pt 2):390-9
2. Norman SB, Wilkins KC, Tapert SF, Lang AJ, Najavits LM. A pilot study of seeking safety therapy with OEF/OIF veterans. J Psychoactive Drugs. 2010 Mar;42(1):83-7
3. Zlotnick C, Johnson J, Najavits LM. Randomized controlled pilot study of cognitive-behavioral therapy in a sample of incarcerated women with substance use disorder and PTSD. [Behav Ther](#). 2009 Dec;40(4):325-36. Epub 2008 Oct 31.
4. Carpentier PJ, Krabbe PF, van Gogh MT, Knapen LJ, Buitelaar JK, de Jong CA. [Psychiatric comorbidity reduces quality of life in chronic methadone maintained patients](#). Am J Addict. 2009 Nov-Dec;18(6):470-80
5. Tenore PL. [Psychotherapeutic benefits of opioid agonist therapy](#). J Addict Dis. 2008;27(3):49-65. Review.
6. Maremmani I, Pacini M, Lubrano S, Perugi G, Tagliamonte A, Pani PP, Gerra G, Shinderman M. [Long-term outcomes of treatment-resistant heroin addicts with and without DSM-IV axis I psychiatric comorbidity \(dual diagnosis\)](#). Eur Addict Res. 2008;14(3):134-42.
7. Peles E, Schreiber S, Naumovsky Y, Adelson M. [Depression in methadone maintenance treatment patients: rate and risk factors](#). J Affect Disord. 2007 Apr;99(1-3):213-20
8. Shaul Schreiber, Einat Peles, Miriam Adelson, Association between improvement in depression, reduced benzodiazepine (BDZ) abuse, and increased psychotropic medication use in methadone maintenance treatment (MMT) patients. Drug and Alcohol Dependence 92 (2008) 79–85

**American Association for the Treatment of Opioid Dependence, Inc.
Opioid Maintenance Pharmacotherapy – A Course for Clinicians**

9. Brooks DJ, Vosburg SK, Evans SM, Levin FR. [Assessment of cognitive functioning of methadone-maintenance patients: impact of adult ADHD and current cocaine dependence.](#) J Addict Dis. 2006;25(4):15-25.
10. Gelkopf M, Weizman T, Melamed Y, Adelson M, Bleich A. [Does psychiatric comorbidity affect drug abuse treatment outcome? A prospective assessment of drug abuse, treatment tenure and infectious diseases in an Israeli methadone maintenance clinic.](#) Isr J Psychiatry Relat Sci. 2006;43(2):126-36
11. Dean AJ, Bell J, Mascord DJ, Parker G, Christie MJ. [A randomised, controlled trial of fluoxetine in methadone maintenance patients with depressive symptoms.](#) J Affect Disord. 2002 Oct;72(1):85-90
12. Cacciola JS, Alterman AI, Rutherford MJ, McKay JR, Mulvaney FD. [The relationship of psychiatric comorbidity to treatment outcomes in methadone maintained patients.](#) Drug Alcohol Depend. 2001 Feb 1;61(3):271-80

Polysubstance Dependence

1. Nyamathi A, Compton P, Cohen A, Marfisee M, Shoptaw S, Greengold B, de Castro V, Reaves M, Hasson A, George D, Leake B. [Correlates of hospitalization for alcohol-using methadone-maintained persons with physical health problems.](#) West J Nurs Res. 2009 Jun;31(4):525-43.
2. Nyamathi A, Cohen A, Marfisee M, Shoptaw S, Greengold B, de Castro V, George D, Leake B. [Correlates of alcohol use among methadone-maintained adults.](#) Drug Alcohol Depend. 2009 Apr 1;101(1-2):124-7
3. Wurst FM, Dürsteler-MacFarland KM, Auwaerter V, Ergovic S, Thon N, Yegles M, Halter C, Weinmann W, Wiesbeck GA. Assessment of alcohol use among methadone maintenance patients by direct ethanol metabolites and self-reports. Alcohol Clin Exp Res. 2008 Sep;32(9):1552-7.
4. Srivastava A, Kahan M, Ross S. The effect of methadone maintenance treatment on alcohol consumption: a systematic review. J Subst Abuse Treat. 2008 Mar;34(2):215-23.
5. Nava F, Manzato E, Leonardi C, Lucchini A. [Opioid maintenance therapy suppresses alcohol intake in heroin addicts with alcohol dependence: preliminary results of an open randomized study.](#) Prog Neuropsychopharmacol Biol Psychiatry. 2008 Dec 12;32(8):1867-72
6. Stenbacka M, Beck O, Leifman A, Romelsjö A, Helander A. [Problem drinking in relation to treatment outcome among opiate addicts in methadone maintenance treatment.](#) Drug Alcohol Rev. 2007 Jan;26(1):55-63.
7. Stenbacka M, Beck O, Leifman A, Romelsjö A, Helander A. [Problem drinking in relation to treatment outcome among opiate addicts in methadone maintenance treatment.](#) Drug Alcohol Rev. 2007 Jan;26(1):55-63.
8. Hillebrand J, Marsden J, Finch E, Strang J, [Excessive alcohol consumption and drinking expectations among clients in methadone maintenance.](#) J Subst Abuse Treat. 2001 Oct;21(3):155-60.
9. Schreiber S, Peles E, Adelson M, [Association between improvement in depression, reduced benzodiazepine \(BDZ\) abuse, and increased psychotropic medication use in methadone maintenance treatment \(MMT\) patients.](#) Drug Alcohol Depend. 2008 Jan 1;92(1-3):79-85.
10. Brands B, Blake J, Marsh DC, Sproule B, Jeyapalan R, Li S. [The impact of benzodiazepine use on methadone maintenance treatment outcomes.](#) J Addict Dis. 2008;27(3):37-48
11. Mol, AJ, et. al. The Role of Craving on Relapse After Discontinuation of Long-Term Benzodiazepine Use, J. Clin Psychiatry 68:12, December 2007

**American Association for the Treatment of Opioid Dependence, Inc.
Opioid Maintenance Pharmacotherapy – A Course for Clinicians**

12. Bramness JG, Kornør H. [Benzodiazepine prescription for patients in opioid maintenance treatment in Norway](#). Drug Alcohol Depend. 2007 Oct 8;90(2-3):203-9
13. Peles E. et. al, Melatonin for perceived sleep disturbances associated with benzodiazepine withdrawal among patients in methadone maintenance treatment: a double-blind randomized clinical trial. Addiction. 2007 Dec; 102(12):1947-53
14. Soares B, Lima Reisser AA, Farrell M, Silva de Lima M. [WITHDRAWN: Dopamine agonists for cocaine dependence](#). Cochrane Database Syst Rev. 2010 Feb 17;2:CD003352. Review
15. Silva de Lima M, Farrell M, Lima Reisser AA, Soares B. WITHDRAWN: Antidepressants for cocaine dependence. Cochrane Database Syst Rev. 2010 Feb 17;2:CD002950. Review.
16. Stitzer ML, Petry NM, Peirce J. [Motivational incentives research in the National Drug Abuse Treatment Clinical Trials Network](#). J Subst Abuse Treat. 2010 Jun;38 Suppl 1:S61-9.
17. Castells X, Kosten TR, Capellà D, Vidal X, Colom J, Casas M. [Efficacy of opiate maintenance therapy and adjunctive interventions for opioid dependence with comorbid cocaine use disorders: A systematic review and meta-analysis of controlled clinical trials](#). Am J Drug Alcohol Abuse. 2009;35(5):339-49.
18. Tzilos GK, Rhodes GL, Ledgerwood DM, Greenwald MK. [Predicting cocaine group treatment outcome in cocaine-abusing methadone patients](#). Exp Clin Psychopharmacol. 2009 Oct;17(5):320-5
19. DeFulio A, Donlin WD, Wong CJ, Silverman K. [Employment-based abstinence reinforcement as a maintenance intervention for the treatment of cocaine dependence: a randomized controlled trial](#). Addiction. 2009 Sep;104(9):1530-8.
20. Peles E, Kreek MJ, Kellogg S, Adelson M, High methadone dose significantly reduces cocaine use in methadone maintenance treatment (MMT) patients. J Addict Dis. 2006;25(1):43-50.
21. Ghitza UE, Epstein DH, Preston KL. [Nonreporting of cannabis use: Predictors and relationship to treatment outcome in methadone maintained patients](#). Addict Behav. 2007 May;32(5):938-49.
22. Epstein DH, Preston KL. [Does cannabis use predict poor outcome for heroin-dependent patients on maintenance treatment? Past findings and more evidence against](#). Addiction. 2003 Mar;98(3):269-79. Review
23. Okoli CT, Khara M, Procyshyn RM, Johnson JL, Barr AM, Greaves L. [Smoking cessation interventions among individuals in methadone maintenance: a brief review](#). J Subst Abuse Treat. 2010 Mar;38(2):191-9
24. Nyamathi AM, Sinha K, Marfisee M, Cohen A, Greengold B, Leake B. [Correlates of heavy smoking among alcohol-using methadone maintenance clients](#). West J Nurs Res. 2009 Oct;31(6):787-98
25. Elkader AK, Brands B, Selby P, Sproule BA, Methadone-nicotine interactions in methadone maintenance treatment patients. J Clin Psychopharmacol. 2009 Jun;29(3):231-8.
26. Richter KP, Hamilton AK, Hall S, Catley D, Cox LS, Grobe J. [Patterns of smoking and methadone dose in drug treatment patients](#). Exp Clin Psychopharmacol. 2007 Apr;15(2):144-53
27. Stein MD, Anderson BJ, Niaura R [Smoking cessation patterns in methadone-maintained smokers](#). Nicotine Tob Res. 2007 Mar;9(3):421-8

**Evidenced-based Psychotherapeutic Interventions /
Treatment Outcome**

1. Veilleux JC, Colvin PJ, Anderson J, York C, Heinz AJ, [A review of opioid dependence treatment: pharmacological and psychosocial interventions to treat opioid addiction](#). Clin Psychol Rev. 2010 Mar;30(2):155-66

American Association for the Treatment of Opioid Dependence, Inc. Opioid Maintenance Pharmacotherapy – A Course for Clinicians

- Bell J, Trinh L, Butler B, Randall D, Rubin G [Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment](#). *Addiction*. 2009 Jul;104(7):1193-200.
- King VL, Burke C, Stoller KB, Neufeld KJ, Peirce J, Kolodner K, Kidorf M, Brooner RK. [Implementing methadone medical maintenance in community-based clinics: disseminating evidence-based treatment](#). *J Subst Abuse Treat*. 2008 Oct;35(3):312-21
- Jones HE, Martin PR, Heil SH, Kaltenbach K, Selby P, Coyle MG, Stine SM, O'Grady KE, Arria AM, Fischer G. [Treatment of opioid-dependent pregnant women: clinical and research issues](#). *J Subst Abuse Treat*. 2008 Oct;35(3):245-59
- Gunderson EW, Fiellin DA. Office-based maintenance treatment of opioid dependence: how does it compare with traditional approaches. *CNS Drugs*. 2008;22(2):99-111. Review
- King VL, Burke C, Stoller KB, Neufeld KJ, Peirce J, Kolodner K, Kidorf M, Brooner RK. Implementing methadone medical maintenance in community-based clinics: disseminating evidence-based treatment. *J Subst Abuse Treat*. 2008 Oct;35(3):312-21
- Sindelar JL, Olmstead TA, Peirce JM., [Cost-effectiveness of prize-based contingency management in methadone maintenance treatment programs](#). *Addiction*. 2007 Sep;102(9):1463-71.
- Ducharme LJ, Knudsen HK, Roman PM. [Evidence-based treatment for opiate-dependent clients: availability, variation, and organizational correlates](#). *Am J Drug Alcohol Abuse*. 2006;32(4):569-76
- Van den Brink W, Haasen C. Evidenced-based treatment of opioid-dependent patients, [Can J Psychiatry](#). 2006 Sep;51(10):635-46.
- Simoens S, Ludbrook A, Matheson C, Bond C. [Pharmaco-economics of community maintenance for opiate dependence: a review of evidence and methodology](#). *Drug Alcohol Depend*. 2006 Sep 1;84(1):28-39
- Stitzer M, Petry, N CONTINGENCYMANAGEMENT FOR TREATMENT OF SUBSTANCE ABUSE. *Annu. Rev. Clin. Psychol*. 2006. 2:411–34
- STEPHAN MAGURA, PH.D., AND ANDREW ROSENBLUM, PH.D. Leaving Methadone Treatment: Lessons Learned, Lessons Forgotten, Lessons Ignored, *THE MOUNT SINAI JOURNAL OF MEDICINE* Vol. 68 No. 1 January 2001

Drug Testing

- Varenbut M, Plater-Zyberk CJ, Worster A, Daiter J. [Does low urine creatinine level indicate the presence of urine alcohol in methadone maintenance treatment patients?](#) *Am J Drug Alcohol Abuse*. 2010 Jul;36(4):199-201
- Gray TR, Dams R, Choo RE, Jones HE, Huestis MA, [Methadone disposition in oral fluid during pharmacotherapy for opioid-dependence](#). *Forensic Sci Int*. 2010 Jul 26
- Shakleya DM, Dams R, Choo RE, Jones H, Huestis MA. Simultaneous liquid chromatography-mass spectrometry quantification of urinary opiates, cocaine, and metabolites in opiate-dependent pregnant women in methadone-maintenance treatment. *J Anal Toxicol*. 2010 Jan-Feb;34(1):17-25
- Drummer, O, Review Article: Drug Testing in Oral Fluid. *Clin Biochem Rev*, Vol 27 August 2006, pp. 147-159
- Drug Testing: A white Paper of the American Society of Addiction Medicine. 2013

Buprenorphine

**American Association for the Treatment of Opioid Dependence, Inc.
Opioid Maintenance Pharmacotherapy – A Course for Clinicians**

1. Kinlock TW, Gordon MS, Schwartz RP, Fitzgerald TT. [Developing and Implementing a New Prison-Based Buprenorphine Treatment Program](#). J Offender Rehabil. 2010 Feb;49(2):91-109
2. Wesson DR, Smith DE. [Buprenorphine in the treatment of opiate dependence](#). J Psychoactive Drugs. 2010 Jun;42(2):161-75
3. Orman JS, Keating GM. [Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence](#). Drugs. 2009;69(5):577-607
4. Ducharme LJ, Roman PM. Opioid treatment programs in the Clinical Trials Network: representativeness and buprenorphine adoption. J Subst Abuse Treat. 2009 Jul;37(1):90-4.
5. Minozzi S, Amato L, Davoli M, Maintenance treatments for opiate dependent adolescent. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD007210. Review
6. Orman JS, Keating GM. [Spotlight on buprenorphine/naloxone in the treatment of opioid dependence](#). CNS Drugs. 2009 Oct 1;23(10):899-902.
7. Ling W. Buprenorphine for opioid dependence. [Expert Rev Neurother](#). 2009 May;9(5):609-16.
8. Schwartz RP, Kelly SM, O'Grady KE, Mitchell SG, Peterson JA, Reisinger HS, Agar MH, Brown BS [Attitudes toward buprenorphine and methadone among opioid-dependent individuals](#). Am J Addict. 2008 Sep-Oct;17(5):396-401.

Dole / Nyswander / Kreek and others

1. Dole VP. [What have we learned from three decades of methadone maintenance treatment?](#) Drug Alcohol Rev. 1994;13(1):3-4
2. Dole VP. Methadone maintenance: optimizing dosage by estimating plasma level. J Addict Dis. 1994;13(1):1-4
3. Dole VP. [Hazards of process regulations. The example of methadone maintenance](#). JAMA. 1992 Apr 22-29;267(16):2234-5
4. Dole VP. [Implications of methadone maintenance for theories of narcotic addiction](#). JAMA. 1988 Nov 25;260(20):3025-9. Review
5. Dole VP, Nyswander ME, DesJarlais D, Joseph H. [Sounding Board. Performance-based rating of methadone maintenance programs](#). N Engl J Med. 1982 Jan 21;306(3):169-71
6. Dole VP, Nyswander ME. [Methadone maintenance: a theoretical perspective](#). NIDA Res Monogr. 1980 Mar;30:256-61
7. Dole VP, Joseph H. Long-term outcome of patients treated with methadone maintenance. Ann N Y Acad Sci. 1978;311:181-9.
8. Dole VP, Nyswander ME [Methadone maintenance treatment. A ten-year perspective](#). JAMA. 1976 May 10;235(19):2117-9.
9. Dole VP, Wolkstein EC. [Vocational rehabilitation of patients on the Beth Israel methadone maintenance program](#). Mt Sinai J Med. 1974 Mar-Apr;41(2):267-71
10. Dole VP, Kreek MJ. [Methadone plasma level: sustained by a reservoir of drug in tissue](#). Proc Natl Acad Sci U S A. 1973 Jan;70(1):10.
11. Dole VP. [Methadone maintenance treatment for 25,000 heroin addicts](#). JAMA. 1971 Feb 15;215(7):1131-4
12. Dole VP. Research on methadone maintenance treatment. Int J Addict. 1970 Sep;5(3):359-73
13. Dole VP, Nyswander ME. Methadone maintenance and its implication for theories of narcotic addiction. Res Publ Assoc Res Nerv Ment Dis. 1968;46:359-66

**American Association for the Treatment of Opioid Dependence, Inc.
Opioid Maintenance Pharmacotherapy – A Course for Clinicians**

14. Dole VP, Nyswander ME Heroin Addiction – A Metabolic Disease. Arch Intern Med July 1967 Vol 120
15. Dole VP, Warner A, Evaluation of Narcotic Treatment Programs, AJPH, November 1967 Vol 57 No 11
16. Dole VP, Nyswander ME, A Medical Treatment for Diacetylmorphine (Heroin) Addiction: A Clinical Trial with Methadone Hydrochloride. JAMA Aug 23, 1965 Vol 193 No 8
17. Dole VP, Nyswander ME, Kreek MJ Narcotic Blockade. Arch Intern Med Vol 118 Oct 1966
18. Dole VP. Thoughts on Narcotic Addiction, Bull N. Y. Acad. Med. February 1965 Vol 41 No 2
19. Kreek MJ. [Overview and historical perspective of four papers presented on research related to the endogenous opioid system.](#) Drug Alcohol Depend. 2010 May 1;108(3):195-9.
20. Kreek MJ, Borg L, Ducat E, Ray B [Pharmacotherapy in the treatment of addiction: methadone.](#) J Addict Dis. 2010 Apr;29(2):200-16.
21. Kreek MJ. Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine Ann N Y Acad Sci. 2000;909:186-216. Review.
22. [Kreek MJ](#), [Zhou Y](#), [Butelman ER](#), [Levrn O](#). Opiate and cocaine addiction: from bench to clinic and back to the bench. [Curr Opin Pharmacol.](#) 2009 Feb;9(1):74-80. Epub 2009 Jan 18.
23. Kreek MJ, Vocci FJ. [History and current status of opioid maintenance treatments: blending conference session.](#) J Subst Abuse Treat. 2002 Sep;23(2):93-105. Review
24. Kreek MJ. [Opioid receptors: some perspectives from early studies of their role in normal physiology, stress responsivity, and in specific addictive diseases.](#) Neurochem Res. 1996 Nov;21(11):1469-88. Review
25. Courtwright DT. [The prepared mind: Marie Nyswander, methadone maintenance, and the metabolic theory of addiction.](#) Addiction. 1997 Mar;92(3):257-65
26. Goldstein A. Heroin addiction: neurobiology, pharmacology, and policy. J Psychoactive Drugs. 1991 Apr-Jun;23(2):123-33. Review
27. Warner A, Dole VP. [The operation of the data system in the methadone maintenance treatment program for heroin addiction.](#) Am J Public Health. 1971 Oct;61(10):2106-14.
28. Novick DM, Pascarelli EF, Joseph H, Salsitz EA, Richman BL, Des Jarlais DC, Anderson M, Dole VP, Nyswander ME [Methadone maintenance patients in general medical practice. A preliminary report.](#) JAMA. 1988 Jun 10;259(22):3299-302.
29. Des Jarlais DC, Joseph H, Dole VP, Nyswander ME. [Medical maintenance feasibility study.](#) NIDA Res Monogr. 1985;58:101-10
30. Des Jarlais DC, Joseph H, Dole VP. Long-term outcomes after termination from methadone maintenance treatment. Ann N Y Acad Sci. 1981;362:231-8.
31. Sapiro JD, The Narcotic Addict as a Medical Patient. Am J Med October 1968 Vol 45